BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX)
8.0500
0.00 (0.00%)
Biocryst Pharma is a biotechnology company focused on developing and commercializing innovative treatments for rare diseases
The company specializes in designing and synthesizing novel small-molecule drugs, particularly those targeting diseases associated with viral infections and genetic disorders. With a commitment to improving patient outcomes, Biocryst employs cutting-edge research and clinical development strategies to bring effective therapies to market, aiming to address unmet medical needs in challenging therapeutic areas.
BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.
BioCryst reported quarterly losses of 28 cents per share, missing the analyst consensus estimate of losses of 24 cents by 16.67% and representing a 26.32% increase over losses of 38 cents per share from the same period last year. The company reported quarterly sales of $93.4 million which beat the analyst consensus estimate of $90.01 million by 3.77% and is a 17.42% increase over sales of $79.55 million from the prior year's quarter.
Companies Reporting Before The Bell • Kosmos Energy (NYSEKOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
Shares of RxSight, Inc. (NASDAQRXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
